Albemarle Corporation Form 10-Q Summary
Business context and reporting period
Albemarle is a global specialty chemicals producer operating primarily through Lithium, Bromine and Catalysts. The unaudited filing covers the three and six months ended June 30, 2022, compared with the corresponding 2021 periods.
Key financial metrics
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Net sales | $1.480 billion | $773.9 million | $2.607 billion | $1.603 billion |
| Gross profit / margin | $580.4 million / 39.2% | $248.4 million / 32.1% | $1.029 billion / 39.5% | $512.1 million / 31.9% |
| Operating profit | $434.1 million | $542.3 million | $746.1 million | $698.2 million |
| Net income attributable to Albemarle | $406.8 million | $424.6 million | $660.2 million | $520.3 million |
| Diluted EPS | $3.46 | $3.62 | $5.61 | $4.51 |
| Adjusted EBITDA | $610.2 million | $194.6 million | $1.042 billion | $424.7 million |
Q2 sales increased 91%, driven by $630.5 million of pricing benefits and $124.4 million of higher volume, partly offset by $25.5 million from the divested Fine Chemistry Services business and $22.9 million of unfavorable currency translation. Six-month sales increased 63%, with pricing contributing $898.9 million and volume $213.9 million.
- Lithium: Q2 sales increased 178% to $891.5 million and adjusted EBITDA increased 352% to $495.2 million, primarily from pricing, index-linked contracts, higher volume and stronger Talison joint-venture earnings.
- Bromine: Q2 sales increased 35% to $377.8 million and adjusted EBITDA increased 46% to $135.7 million, supported by pricing and demand across products.
- Catalysts: Q2 sales increased 42% to $210.3 million, but adjusted EBITDA declined 54% to $9.8 million because higher utility, raw-material and freight costs outweighed pricing and volume gains.
Operating profit and EPS comparisons were affected by the $429.4 million pretax gain from the 2021 sale of the FCS business. Excluding that comparison distortion, 2022 benefited from substantial pricing, volume and joint-venture earnings growth. Q2 interest and financing expense rose to $41.4 million, including a $19.2 million loss on early debt extinguishment.
Cash flow, balance sheet, debt and liquidity
- Cash provided by operating activities was $60.3 million in the first six months of 2022, down from $385.9 million in 2021. Working-capital outflows were $888.0 million, mainly from higher receivables and inventories associated with higher lithium pricing and sales, and the $332.5 million final payment on the Huntsman settlement.
- Capital expenditures were $502.6 million versus $396.9 million in the prior-year period. Management expects 2022 capital expenditures of $1.3 billion to $1.5 billion, primarily for lithium growth and capacity expansion.
- Cash and cash equivalents increased to $930.6 million from $439.3 million at December 31, 2021. Foreign subsidiaries held $367.2 million of cash.
- Total debt shown on the June 30 balance sheet was approximately $3.46 billion, including $251.3 million of current maturities and $3.21 billion of noncurrent debt, compared with approximately $2.39 billion at December 31, 2021.
- In May 2022, Albemarle issued $1.7 billion of senior notes due 2027, 2032 and 2052. Proceeds repaid commercial paper and $425 million of notes due 2024 and funded general corporate purposes. The company also drew $250 million under its 2019 Credit Facility.
- There were no commercial paper borrowings outstanding at June 30, 2022. Available capacity was approximately $1.5 billion under the commercial paper program and credit agreements, plus $200.7 million under other credit lines. Management reported compliance with debt covenants.
- Net current assets were $1.57 billion at June 30, 2022, compared with $133.6 million at year-end 2021. Management expects cash on hand, operating cash flow and borrowing capacity to fund operations, debt service, capital expenditures, acquisitions, pensions and dividends for the foreseeable future.
Material changes versus the prior comparable period
- Pricing and volume growth materially improved sales, gross profit and adjusted EBITDA, led by Lithium.
- Gross margin expanded to 39.2% in Q2 from 32.1%, despite higher natural-gas, freight, raw-material and lithium-related commission costs.
- Q2 net income attributable to Albemarle declined 4% and diluted EPS declined 4% because the prior-year period included the FCS divestiture gain. Six-month net income increased 27% and diluted EPS increased 24%.
- Equity income from unconsolidated investments increased to $128.2 million in Q2 from $18.0 million, primarily due to stronger pricing and volume at the Talison lithium joint venture.
- Other comprehensive loss was $113.6 million in Q2, primarily from unfavorable foreign-currency movements, compared with comprehensive income of $22.0 million in Q2 2021.
- The company completed the $665 million Huntsman settlement, with the final $332.5 million payment made in May 2022.
Guidance, outlook, commentary and risks
- Management expects Lithium results to be higher year over year in 2022, driven primarily by pricing and volume. Lithium market indices had increased 60% to 130% since the beginning of the year, but a material price decline would negatively affect the outlook.
- Management expects Bromine 2022 sales and profitability to grow 15% to 20%, assuming continued raw-material availability and ongoing pricing and cost savings.
- Management now expects Catalysts results to decline 25% to 65% year over year because of inflation in freight and input costs, including European natural-gas volatility related to the war in Ukraine. Contingent business-interruption insurance recoveries could total up to $53 million in 2022 and 2023, but receipt is uncertain.
- La Negra, Chile was in commissioning and qualification. Kemerton Train II completion was delayed to the second half of 2022, with commercial sales volume expected to begin in 2023. Wodgina first-train spodumene production was achieved in May and second-train production in July.
- Albemarle expected to close its approximately $200 million Tianyuan acquisition in the second half of 2022. Tianyuan has designed annual conversion capacity of up to 25,000 metric tons of lithium carbonate equivalent.
- Construction of the Meishan lithium conversion plant in China was underway and expected to finish by the end of 2024; Zhangjiagang was in engineering. Each plant initially targets 50,000 metric tons per year.
- Key risks include lithium-price volatility, contract renegotiations, production or capacity delays, raw-material and energy costs, foreign exchange, inflation and interest rates, supply-chain constraints, COVID-19 impacts, geopolitical instability, environmental liabilities, cybersecurity, regulatory changes and performance of joint-venture partners.
- The company is cooperating with the DOJ, SEC and Dutch Public Prosecutor regarding potential improper payments by third-party sales representatives in the Catalysts business. The duration, outcome and costs remain uncertain; management does not currently expect a material effect on financial condition or liquidity, but an adverse resolution could materially affect a particular period.
- Recorded environmental liabilities were $46.3 million, with management estimating an additional reasonably possible exposure of $10 million to $24 million before tax. The company also disclosed approximately $87.5 million of bank guarantees and letters of credit.
- The six-month 2022 interest expense included a $17.5 million correction of prior-period overstatement of capitalized interest. Management concluded the correction was not material to prior periods or the current six-month period.
Investor verification priorities
- Verify whether lithium pricing and index-linked contract exposure remain sustainable and how rapidly market prices affect realized prices and margins.
- Track Lithium capacity ramp-ups at La Negra, Kemerton, Wodgina and Tianyuan, including construction, commissioning and acquisition-closing milestones.
- Reconcile the planned $1.3 billion to $1.5 billion of 2022 capital expenditures with operating cash generation and incremental borrowing needs.
- Monitor debt growth, variable-rate exposure, refinancing requirements beginning in 2025 and compliance with the 3.50:1 net funded debt-to-EBITDA covenant.
- Assess Catalysts cost inflation, the strategic review, and the uncertain potential insurance recoveries of up to $53 million.
- Follow the DOJ, SEC and Dutch investigations, environmental claims, and any additional costs related to the Huntsman matter or other contingencies.